Seattle Children's
HOSPITAL · RESEARCH · FOUNDATION

UW Medicine
SCHOOL OF MEDICINE

January 6, 2019

Rexford S. Ahima
The Journal of Clinical Investigation
P.O. Box 7226
Ann Arbor, Michigan 48107, USA

Dear Dr. Ahima,

Thank you for the thoughtful review of our manuscript. In regards to the clinical checklist, we have previously reported the clinical results for our CD19CAR trial *(1)*. Keith Kalinowski of the editorial team has confirmed that we could move forward without the clinical checklist as the information has been previously published.

Thank you for your consideration.

Sincerely,

Michael Jensen, MD
Jan & Jim Sinegal Endowed Chair, Childhood Cancer Research
Professor, Department of Pediatrics, Univ. of Washington School of Medicine
Adjunct Professor, Bioengineering, Univ. of Washington
Director, Ben Towne Center for Childhood Cancer Research, SCRI
Joint Member, Program in Immunology, FHCRC
Co-Head, Program in Immunology and Vaccine Development, UW/FHCRC Cancer Consortium
Executive Director, CureWorks
michael.jensen@seattlechildrens.org (206) 987-1241

1. R. A. Gardner, O. Finney, C. Annesley, H. Brakke, C. Summers, K. Leger, M. Bleakley, C. Brown, S. Mgebroff, K. Spratt, V. Hoglund, C. Lindgren, A. P. Oron, D. Li, S. R. Riddell, J. R. Park, M. C. Jensen, Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults, *Blood* , blood-2017-02-769208 (2017).

.